Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16596822 | 0.91 | CYP1A2 (0.41) | NOTUMPIK3CDALDH1A1KDM4ENPSR1 | |
| SCHEMBL16596147 | 0.89 | NOTUM (0.48) | NOTUMALDH1A1FAAHMGLLKDM4E | |
| SCHEMBL16596152 | 0.86 | PIK3CD (0.47) | NOTUMPIK3CDFAAHMGLLKDM4E | |
| SCHEMBL16596154 | 0.85 | ALDH1A1 (0.43) | NOTUMPIK3CDALDH1A1KDM4ENPSR1 | |
| SCHEMBL18708792 | 0.85 | PIK3CD (0.41) | NOTUMPIK3CDFAAHMGLLMETAP2 | |
| SCHEMBL16591320 | 0.84 | PIK3CD (0.40) | NOTUMPIK3CDFAAHMGLLKDM4E | |
| SCHEMBL16689262 | 0.82 | PIK3CD (0.45) | NOTUMPIK3CDFAAHMGLLMETAP2 | |
| SCHEMBL14649148 | 0.82 | PIK3CD (0.45) | NOTUMPIK3CDFAAHMGLLMETAP2 | |
| SCHEMBL16596185 | 0.79 | PDE7A (0.45) | PIK3CDCYP1A2 | |
| SCHEMBL16596950 | 0.78 | PIK3CD (0.52) | PIK3CDSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657007-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9512114-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160318914-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2016-11-03 | — | — | US | disclosed |
| US-20150087658-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2015042078-A2 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318914-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MYD88 | NOTUM 2338/4885PIK3CD 2/4885ALDH1A1 2302/4885 |
| US-20150087658-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MYD88 | NOTUM 2338/4885PIK3CD 2/4885ALDH1A1 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.